An Elderly with Type 2 Diabetes (T2D) and Arteriosclerosis Treated by Imeglimin (Twymeeg)

Sakamoto K, Okada M, Iwatsuki N, Ogawa T and Bando H

Published on: 2026-02-21

Abstract

The patient is 78-year-old female with type 2 diabetes (T2D), treated by imeglimin (Twymeeg) from October 2022. Her BMI was 24.7kg/m2 and HbA1c was stable for years. She has continued petite-low carbohydrate diet (LCD) for years. Pulse wave velocity (PWV) showed Cardio-Ankle Vascular Index (CAVI) 9.4/9.4 (right/left) and ankle-brachial index (ABI) 0.96/0.96, which seems to be rather atherosclerotic. Head MRI/MRA showed cerebral atrophy and age-related changes of brain blood vessels. By Lipid-Lowering Drug (LLD) from October 2024, LDL-cholesterol decreased from 138 to 68mg/dL for 6 months. Thus, she keeps stable condition, probably from LCD and regular oral hypoglycemic agents (OHAs).

Keywords

Petite-low carbohydrate diet (LCD); Imeglimin (Twymeeg); Trials of IMeglimin for Efficacy and Safety (TIMES); Oral hypoglycemic agents (OHAs); Lipid-Lowering Drug (LLD)

Introduction

In the developed countries, elderly people are likely to possess lifestyle-related disease or atherosclerotic cardiovascular disease (ASCVD). Among them, diabetic patients has higher risk for ASCVD and atherosclerosis, leading to various comorbidities and complications [1]. Furthermore, diabetic pathophysiology will cause macroangiopathy and microangiopathy with various impairment of organ dysfunction [2]. When providing medical care to elderly people, appropriate management must be carried out after considering each organ or systematic axes investigation, such as diabetes, cardiovascular evaluation, metabolic aspect, arteriosclerosis, lipids, and renal functions [3].

Management for LDL-cholesterol (LDL-C) is generally recommended for preventing ASCVD, and then diabetic patients are often treated as a high-risk group in guidelines [4]. However, the decision on whether or not to use drug intervention in the elderly is not simple, and various perspectives are found that individual assessment is necessary with adequate balancing. They include benefits for the reduction of cardiovascular events, risks for side effects or polypharmacy, functional status of ADL and cognition, and evaluation using Geriatric Research and Clinical Guidelines [5]. Among them, some studies have showed potential disadvantages associated with a strategy of lowering LDL-C too drastically [6].

Authors and collaborators have continued clinical practice and related research for years [7,8]. Among them, various impressive cases with diabetes and arteriosclerosis have been reported associated with perspectives [9,10]. Our clinical team has recently experienced an impressive female patient. She has type 2 diabetes (T2D), hypertension, and arteriosclerotic changes, and her clinical progress with related perspectives are also described in this article.

Presentation Of Cases

History and Physicals

The patient is 78-year-old female who was treated by type 2 diabetes (T2D), hypertension and Gastroesophageal Reflux Disease (GERD). She has kept stable control of HbA1c and blood pressure for years. She has started to take imeglimin (Twymeeg) from 2022. Her physical examination showed in the followings: Vitals, consciousness, conversation and speech were normal. No changes were found for her face, head, neck, heart, lung, abdomen, extremities or neurological tests. Her physique showed 154.7cm in height, 59.0kg in weight, and 24.7 kg/m2 in body mass index (BMI). Clinical progress in blood chemical exam was summarized in Figure 1. The results showed stable for HbA1c, liver function, renal function and complete blood count (CBC).

Clinical progress

The HbA1c value was increased to 7.0% in Oct 2022, and then she started to take imeglimin (Twymeeg) (Figure 1). Her HbA1c value were almost stable and she has continued her regular life for years. When LDL value was increased to 138 mg/dL in Oct 2024, she was provided rosuvastatin for the treatment of dyslipidemia. After that, LDL value was decreased remarkably to 68mg/dL for 6 months (Figure 1).

Figure 1: Bood Chemistry and Related Treatments.

Several Examinations

Several basic exams were performed. Chest X-ray showed unremarkable findings, and Electrocardiogram (ECG) revealed regular pulse 76/min, ordinary sinus rhythm (OSR), and no remarkable ST-T changes. Urinalysis presented that protein (-), glucose (++), occult blood (-), urobilinogen (+/-), and ketone bodies (-). She underwent clinical test of pulse wave velocity (PWV) (Figure 2).

Figure 2: Result of Pulse Wave Velocity (PWV).

It revealed normal ranges of ECG, PCG, bilateral forearms and feet. The value of Cardio-Ankle Vascular Index (CAVI) showed 9.4/9.4 (right/left), that is rather arteriosclerotic for standard range as 8.6+/-0.8 (Figure 3). The ankle-brachial index (ABI) showed 0.96/0.96 (right/left) that is within normal limit [11]. The detailed results of PWV presented that L (119) = L1 (61) + L2 (32) + L3(26), PEP 89, ET 312, R-AI 1.30 and PEP/ET 0.27. These data were in the standard range compared with her age.

Figure 3: Result of CAVI Taken From PWV.

Head MRI/MRA

By head MRI, cerebral atrophy and ventricular enlargement were observed, along with a slight increase in small signal changes in the cerebral white matter and subcortical areas (Figure 4a). Faint signal changes were also observed around the ventricles. However, no significant hyperintensity was observed on diffusion-weighted imaging (DWI), and no new vascular lesions or masses were found.

Figure 4: Result of Head MRI/MRA.

a. Cerebral Atrophy by MRI.

MRA revealed slight vascular tortuosity. The tortuosity of the left internal carotid artery siphon appeared slightly narrowed (Figure 4b). No other severe stenosis or aneurysms were found in the main trunk. Overall, age-related changes associated with hypertension and ischemia were somewhat noticeable. Further follow-up is considered necessary, including the assessment of risk factors for vascular disorders.

Figure 4: Result of Head MRI/MRA.

b. Age-Related Changes by MRA.

Ethical standards

Current report is complied with the Helsinki Declaration [12]. Some commentary presented the protection for personal right. Its principle reveals ethical rule of human patients in clinical research. Necessary guideline is from Ministry of Education, Culture, Sports, Science Technology and Ministry of Health, Labour and Welfare, Japan. Authors and co-researchers have established ethical committee in Sakamoto hospital. It included the president, physicians, registered nurse, pharmacist, dietician and legal professional. We have discussed current protocol enough, and agreed the protocol, and had informed consent from the patient.

Discussion

The patient was a 78-year-old woman with no significant medical history, and her blood sugar and blood pressure had been recently well controlled. She also had no particular biopsychosocial problems. Head MRI/MRA also showed no obvious cerebrovascular accident (CVA). Medical problems in this case can be summarized in the following. They are #1 T2D, #2 hypertension, #3 GERD, #4 constipation, #5 insomnia and #6 cerebral arteriosclerosis. Related medications were as follows: #1: imeglimin (Twymeeg) 2000mg/day, empagliflozin 10mg/day, vildagliptin 100mg/day, metformin 500mg/day, #2: amlodipine 5mg/day, valsartan 80mg/day, #3: lansoprazole 15mg/day, #4: picosulfate 5mg/day, #5: lemborexant 5mg/day, #6: aspirin (acetylsalicylic acid) 100mg/day. 

Concerning pharmacotherapy for T2D, she continued imeglimin (Twymeeg) until now, where general clinical course seemed to be rather stable. The international muti-center large study for imeglimin has been known for several reports, which are Trials of IMeglimin for Efficacy and Safety (TIMES) [13]. For the TIMES 2 study, clinical efficacy of combination therapy for oral hypoglycemic agents (OHAs) were reported [14]. They showed that -0.46% as monotherapy, -0.67% as biguanide, -0.85% as α-glucosidase inhibitor (α-GI), -0.57% as SGLT2-i, and -0.92% as DPP4-i. In the current case, she was provided combined OHAs of imeglimin, biguanide, SGLT2-i, and DPP4-i. Consequently, clinically stable diabetic situation seemed to be from her eating habit and combined OHAs [15].

Regarding the treatment of dyslipidemia in this case, she showed decreased LDL-C value by the administration of rosuvastatin. Analysis of the database of 700,000 people was found for diabetes and lipid [16]. While LDL-C target achievement is improving, many people still fail to achieve their goals, suggesting the need for drug intervention. It is required to evaluate the relationship between statin treatment and mortality in elderly diabetic patients, and to examine the possibility of improving outcomes with statins [17]. However, opposite result was found for negative efficacy of treating lipid profile [18]. Regardless of Lipid-Lowering Drug (LLD) use, negative relationship may exist with decreased cholesterol value and increased dementia, diabetes and atrial fibrillation (AF).

Regarding eating habit, she continued petite-LCD but did not want to continue strict restriction of taking carbohydrate [19]. As nutritional treatment, she began petite-LCD after consulting her about the possible continuing diet therapy for long.  Actual LCD has three types of practical methods that are petite-LCD, standard-LCD and super-LCD. They have carbohydrate ratio for 40%, 26%, and 12%, respectively [20]. For effective diet therapy, the comparison with LCD and low-fat diets (LFD) has been discussed so far. A recent study included 7 RCTs from moderate carbohydrate regimens (30-45%) to very low-carbohydrate ketogenic diet (VLKD) (<10%) [21]. In contrast, LFDs have carbohydrate 50-60%, lower fat 20-30%, and protein 15-20%. Thus, compared studies will be encouraged for various situations in the future.

Some limitation may be present in this report. Current case showed rather long history of T2D and stable glucose variability by LCD and combined OHAs. She has not have apparent diabetic macroangiopathy or microangiopathy so far, but her future clinical progress should be followed up with close attention.

In summary, 78-year-old female case with T2D, hypertension treated by imeglimin was presented. Some perspectives were included concerning diet therapy, diabetic control, arteriosclerosis, and other medical problems. We hope that this article will become useful and meaningful reference for diabetic practice and research in the future.

Conflict of interest: The authors declare no conflict of interest.

Funding: There was no funding received for this paper.

References

  1. Bhaskar R, Nagayach A, Mishra PK, Singh KK, Han SS. Chapter 12 - Precision nutrition and personalized intermittent fasting: tailoring therapeutics for optimal aging. Eds: Singh AK, Sinha JK, Seetharam RN. The Potential of Intermittent Fasting in Age-related Diseases and Precision Antiaging Therapeutics. Academic Press. 2026; 269-282.
  2. Lu Z, An N, Sheng S, Hong M, Deng P, Wu J, et al. Machine learning combining external validation to explore the immunopathogenesis of diabetic foot ulcer and predict therapeutic drugs. PLoS One. 2025; 20: e0328906.
  3. Peng Y, Li R, Li H, Zhou J, Liu X, Valente G, et al. Emerging Therapeutic Strategies in Anti-Aging Medicine: A Comprehensive Review. Medicine Bulletin. 2026; 2: 94-123.
  4. American Diabetes Association Professional Practice Committee for Diabetes*. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026; 49: S216-S245.
  5. Rossi A, Masi D, Zilich R, Baccetti F, Baronti W, Falcetta P, et al. Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists database. Cardiovasc Diabetol. 2025; 24: 94.
  6. Wang TY, Chang WL, Wei CY, Liu CH, Tzeng RC, Chiu PY. Cholesterol Paradox in Older People with Type 2 Diabetes Mellitus Regardless of Lipid-Lowering Drug Use: A Cross-Sectional Cohort Study. Nutrients. 2023; 15: 3270.
  7. Bando H, Iwatsuki N, Okada M, Ogawa T, Sakamoto K. A Diabetic Case of Occasional Hemorrhoidal Bleeding with Clinical Improvement by Imeglimin (Twymeeg). Int J Case Rep Clin Image. 2026; 7: 255.
  8. Ebe K, Wood M, Bando H. In Memory of Dr. Richard K. Bernstein, April 17. Int J Endocrinol Diabetes. 2025; 8: 188.
  9. Kawahito A, Sueki E, Aihara A, Ikezoe M, Fukushima N, Bando H, et al. Remarkable Reduction of HbA1c and Weight by Low Carbohydrate Diet (LCD) and Imeglimin (Twymeeg) in a Diabetic Male. Int J Endocrinol Diabetes. 2026; 9: 201.
  10. Wood M,  Bando  H, Ebe  Immune  Function  Augmentation  in  Low-Carbohydrate  Diet  (LCD). Int  J Endocrinol Diabetes. 2025; 8: 186.
  11. Gupta A, Singh R, Bhadada SK, Jude EB, Rastogi A. Ankle brachial index and brachial-ankle pulse wave velocity as predictor for major adverse limb events and all-cause mortality in diabetes. Diabetes Metab Syndr. 2025; 5: 103239.
  12. General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014; 81: 14-8.
  13. Reilhac C, Dubourg J, Thang C, Grouin JM, Fouqueray P, Watada H. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period. Diabetes Obes Metab. 2022; 24: 838-48.
  14. Dubourg J, Fouqueray P, Quinslot D, Grouin JM, Kaku K. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial. Diabetes Obes Metab. 2021; 24: 609-19.
  15. Bando H, Iwatsuki N, Okada M, Ogawa T, Sakamoto K. Relieved Type 2 Diabetes (T2D) By Petite Low Carbohydrate Diet (LCD), Equmet and Twymeeg. J Biomed Sci Res. 2024; 6: 191.
  16. Rossi A, Masi D, Zilich R, Baccetti F, Baronti W, Falcetta P, et al. Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists database. Cardiovasc Diabetol. 2025; 24: 94.
  17. Fan Y, Wang J, Wu H, Dai L, Wang L, Gu L. Effect of statin treatment on mortality in elderly patients with type 2 diabetes mellitus patients: a retrospective cohort study. BMC Geriatr. 2023; 23: 549.
  18. Wang TY, Chang WL, Wei CY, Liu CH, Tzeng RC, Chiu PY. Cholesterol Paradox in Older People with Type 2 Diabetes Mellitus Regardless of Lipid-Lowering Drug Use: A Cross-Sectional Cohort Study. Nutrients. 2023; 15: 3270.
  19. Kusumoto T, Bando H, Hayashi K, Yasuoka E, Shibata M, Takagishi H. Actual Meal of Low Carbohydrate Diet (LCD) for Diabetic Patient Treated by Effective Imeglimin (Twymeeg). Asp Biomed Clin Case Rep. 2023; 6: 178-85.
  20. Bando H, Ebe K. Beneficial and Convenient Method of Low Carbohydrate Diet (LCD) as Petite, Standard and Super LCD. Asp Biomed Clin Case Rep. 2023; 7: 1-4.
  21. Anyang Kaakyire D, Abdelfattah OO, Kumar A, Qadeer S. Efficacy of Low-Carbohydrate Diets Versus Low-Fat Diets in Glycemic Control Among Patients With Type 2 Diabetes: A Systematic Review. Cureus. 2025; 17: e77004.